films from outside sources. 
4.2 Complete pretreati^ent immunologic evaluation to include: 
a. Freeze storage of 4 ml serum for future measurement of antibody levels. Antigens to be 
tested can include Hepatitis B, HIV, Tetanus, Diphtheria, Pneumococcal polysaccharide 
types 1, 2, and 3, Hemophilus influenzae, Keyhole limpet hemocyanin (KLH), 0X174, 
Riff Valley Fever (RVF) virus, and Venezuelan equine encephalitis (VEE) virus. The 
final panel to be measured will be at the discretion of PI depending upon the clinical 
situation, history of previous immunizations and gammaglobulin replacement therapy, 
and antigens used in the evaluation of patient response to treatment with gene transduced 
lymphocytes. 
b. Isohemagglutinins and quantitative immunoglobulins (A,G,M and E) 
c. Cellular phenotype of peripheral blood by dual label FACS analysis (CD3/HLA-DR, 
CD4/CD8, CD45/CD14, CD5/CD20, CD2/CD16) 
d. In vitro lymphocyte proliferative responses to mitogens (PHA, PWM, Con-A), soluble 
antigens (Diphtheria, Tetanus, Candida albicans), alloantigen and anti-CD3. In vitro 
analysis of B cell responsiveness, helper and suppressor T cell function will also be 
performed. 
e. Measurement of ADA concentration in peripheral mononuclear cells and concentrations of 
deoxyadenosine in red cells, serum, and urine, and dAXP in RBC and blood mononuclear 
cells as available and appropriate. 
f. Determination of cytotoxic cell function (NK, LAK, CML and virus modified self target 
killing, as avaliable) 
g. DTH skin test panel (CMI Multitest or equivalent) 
4.3 Routine Laboratory Tests. 
a. Chemistry panel to include: Uric acid, Ca, Phos, SGOT, SGPT, Aik. P’tase, LDH, bilirubin, 
BUN, creatinine, total protein, glucose. 
b. CBC, differential and platelets 
c. Urinalysis 
d. Non-serologic HIV test 
4.4 Review of PEG-ADA treatment diary of growth, illnesses, etc. if available. 
Recombinant DNA Research, Volume 14 
[225] 
